NeuroPace Receives FDA Feedback on IGE PMA Supplement
MOUNTAIN VIEW, Calif., July 28, 2026 NeuroPace announced that the U.S. Food and Drug Administration (FDA) has informed the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MOUNTAIN VIEW, Calif., July 28, 2026 NeuroPace announced that the U.S. Food and Drug Administration (FDA) has informed the...
Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...
